Primary Hepatocellular Carcinoma

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
CT-011Phase 1/21 trial
Active Trials
NCT00966251Terminated2Est. Jun 2011
Virogin Biotech
Virogin BiotechBC - Richmond
1 program
1
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 InjectionPhase 1/21 trial
Active Trials
NCT06124001Not Yet RecruitingEst. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Virogin BiotechRecombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
TevaCT-011

Clinical Trials (2)

Total enrollment: 2 patients across 2 trials

NCT06124001Virogin BiotechRecombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Start: Nov 2023Est. completion: Jun 2026
Phase 1/2Not Yet Recruiting

Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

Start: Oct 2009Est. completion: Jun 20112 patients
Phase 1/2Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space